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Aim: To report the Italian data deriving from the ESC-EORP Atrial Fibrillation Ablation 
Long-Term (AFA LT) registry.  
Methods and results: Ten Italian centers enrolled up to 50 consecutive patients 
undergoing AF ablation. Of 318 patients included 5 (1.6%) did not undergo catheter 
ablation, 1 had ablation partially done and 62 were lost at 1-year follow-up. Women were 
less represented (23.6%) and the median age was 60.0 years. 195 patients (62.3%) suffered 
paroxysmal AF, whereas only 9 (2.9%) had long-standing persistent AF. Most Italian 
patients (92.3%) were symptomatic but suffering less symptomatic events than patients 
enrolled in other countries (median of 2 events in the month preceding the ablation vs. 3, 
respectively; p<0.0001). The main finding of the study is that the success rate at 1-year, 
with and without antiarrhythmic drugs, was 76.4%, consistent with other participating 
countries (73.4%). This result was obtained however with a significantly lower prevalence 
of 1-year adverse events (7.3% vs. 16.6%, p<0.0001). Procedure duration and fluoroscopy 
total time resulted shorter in Italy (145 vs. 160, p=0.0005, and 16.9 vs. 20.0 minutes, 
p=0.0018, respectively); however, radiation dose per body surface area was greater (37.5 
vs. 26.0 mGy/cm2, p=0.0022). 
Conclusion: The demographic characteristics of patients undergoing AF ablation are 
similar to those reported in other countries. The success rate in Italy is consistent with 
other countries, whereas the complications rate is lower.  
 






Atrial fibrillation (AF) affects 2.04% of the Italian population[1] and represents the most 
common sustained tachyarrhythmia worldwide[2]. Its prevalence increases with age, as, 
according to the recent FAI project[3], 8.1% (9.1% in men and 7.3% in women) of 
patients over 65 years of age are affected. Moreover, it has been estimated that, in Italy, by 
2060 about 1'892'000 people over 65 years of age will be affected by the arrhythmia, in 
contrast with the estimated 1'081'000 by 2016[3]. AF has a severe impact both on 
cardiovascular events[4] and quality of life[5], being associated with an increased risk of 
dementia[6,7], stroke[8], systemic thromboembolic events[9], mortality and sudden 
cardiac death[10].  
Either in patients who remain symptomatic despite antiarrhythmic drugs, or as first line 
approach in selected patients, pulmonary veins isolation via catheter ablation is a widely 
used approach for the treatment of AF[11]. For this reason, in 2012, the European Society 
of Cardiology (ESC) and European Heart Rhythm Association (EHRA) promoted a 
multicentre, prospective, observational registry to collect a large dataset on AF ablation in 
European and Mediterranean countries. 
The ESC-EORP AF ablation long-term registry[12] provides a real-world snapshot 
of the management of patients undergoing AF ablation, as it allows to monitor indication, 
efficacy and complication rates of AF ablation in common practice. Its observational 
design, in addition, allows describing AF clinical management prior to the ablation 
procedure, highlighting improvable critical issues and guiding future research towards 




We hereby report the Italian data from the ESC-EORP AF ablation long-term registry, 
including in-hospital and 1-year follow-up. 
 
Methods 
The ESC-EORP AF ablation long-term registry has been previously described [12]. 
Briefly, in Italy, enrollment started in April 2012 and terminated in April 2015. Data 
collection was concomitant with enrollment and the study terminated 1 year after the last 
enrolled patient’s AF ablation.. All centres with an electrophysiological laboratory 
performing AF ablation were invited to enroll all (with a maximum limit of 50) 
consecutive patients undergoing the procedure. No exclusion criteria were imposed, except 
for refusal to sign informed consent. Data were collected at enrollment time, during the 
procedure and hospitalization and at 12-months follow-up. Collected data included 
demographics and anamnestic information of patients, procedural and post-procedural 
data, and information on clinical course and medications during follow-up. Definitions of 
paroxysmal, persistent and long-standing persistent AF followed 2010 ESC AF guidelines. 
Definition of lone AF and AF recurrences have been specified elsewhere [12]. 
Statistical analyses 
Continuous variables were reported as median and interquartile range (IQR). Categorical 
variables were reported as percentages. Kruskal-Wallis test was used to compare 
continuous variables among groups. Pearson's chi-squared and Fisher's exact test were 
used for among-groups comparison for categorical variables, the latter if the expected 




differences before and after ablation procedure. Kaplan-Meier curves were built for time 
to first recurrence and comparison among groups was performed using log-rank test. P 
values <0.05 were considered statistically significant. 
 
Results 
Ten Italian centers participated in data collection. Of 318 patients included, 5 (1.6%) did 
not undergo catheter ablation and 1 had ablation partially done. No patients died during 
the in-hospital phase. Of the 313 patients discharged after the procedure,  
62 were lost at follow-up. (Fig. 1) 
Patients’ demographic characteristics are reported in Table S1 (Supplementary material). 
Median age was 60.0 years (IQR 54.0 - 66.0). 195 patients (62.3%) suffered paroxysmal 
AF, whereas only 9 (2.9%) had long-standing persistent AF. Women were less represented 
(23.6%). The two most common cardiovascular risk factors were hypertension and 
hypercholesterolemia, affecting 61.1% and 32.5% of patients, respectively. 
Hypertension was also the most common underlying disorder, either as hypertensive 
cardiomyopathy (66.2% of patients without lone AF or hypertension without 
cardiomyopathy) or as hypertension in the absence of hypertensive cardiomyopathy 
(15.8%). Lone AF was detected in 31% of the cases. Ischemic thromboembolic events had 
occurred in 6.4%. The median number of AF episodes the month before enrollment was 
2.0 (IQR 1.0 - 4.0): the majority of patients experienced palpitations, fatigue and/or 
dyspnoea (87.8%, 37.8% and 32.3% respectively); 14.9% complained generic weakness 




Overall, based on symptoms, more than nine out of ten patients were classified as 
EHRA score 2 (76.9%) or 3 (13.8%), whereas only 7.7% were asymptomatic. 
Table 1 shows the comparison of baseline clinical characteristics between Italy and the 
other participating countries. The Italian population included a lower percentage of women 
(p = 0.0010), whereas an increased percentage of Caucasian patients  
(p < 0.0001) was found. Obesity (BMI > 30 kg/m2), and former smoking were less 
prevalent in Italy, whereas hypertension was more diffused. Symptoms were assessed, 
both in terms of severity (EHRA score) and quality: in this respect, Italian patients 
experienced less symptomatic episodes (p < 0.0001). Noticeable differences were present 
in terms of the underlying AF mechanism (with a greater portion of cases accountable to 
hypertensive cardiomyopathy, p < 0.0001, and fewer to coronary artery disease, p = 
0.0063, chronic heart failure, p < 0.0001, and hypertension without known hypertensive 
cardiomyopathy, p < 0.0001) and AF precipitating factors (fewer episodes due to physical 
exercise, p < 0.0001, or alcohol abuse, p = 0.0003, respectively). 
With regard to clinical management, in Italy, a larger portion of patients underwent 
cardioversion (p = 0.0176) and antiarrhythmic drug trial (p = 0.0279). A greater 
percentage of patients were administered flecainide and disopyramide, whereas fewer 
were under class III agents (amiodarone, dronedarone and sotalol) and propafenone.  
Eventually reasons of referral for AF ablation, classified as in the 2010 ESC AF 
guidelines, emerged as slightly different: in Italy, a greater portion of patients performed 




0.0374), quality of life improvement (p < 0.0001) or desire to discontinue drugs (p = 
0.0379). 
Intraprocedural details 
Table S2 (Supplementary material) reports the technical characteristics of the procedure in 
Italy. Comparison of procedural details between Italy and the other enrolling countries is, 
instead, reported in Table 2. The use of rotational angiography for 3D reconstruction is 
more common in Italy, whereas circular mapping catheters are more commonly used in 
other countries. In Italy image fusion with pre-acquired cardiac magnetic resonance 
images is more commonly performed (p < 0.0001). On the other hand, CT scan images 
integration is less performed (p < 0.0001). Of note in Italy a lower percentage of 
procedures are performed with general anesthesia (p < 0.0001). With regard to source of 
energy used, cryoablation is less diffused in Italy (p < 0.0001) compared to other 
countries, in favor of radiofrequency with open irrigation (p < 0.0001). Procedure duration 
(p = 0.0005) and fluoroscopy total time (p = 0.0018) are shorter in Italy, however radiation 
dose per body surface area appears greater (p = 0.0022).  
With regard to intraprocedural outcomes of efficacy, in Italy, PV entrance block was 
achieved in a greater portion of patients in the left superior and both right pulmonary 
veins. In addition, a greater portion of patients underwent mitral isthmus (p = 0.0354) and 
posterior line (p < 0.0001) ablation, as well as elimination of fractionated electrograms (p 
< 0.0001). 
Adverse events 
Adverse events associated with AF catheter ablation in Italy and the other participating 




Italian practice, the overall prevalence of adverse events, occurring both in-hospital and at 
1-year follow-up, was 7.3%.  
Compared to other countries Italian, patients experienced less adverse events  
(p < 0.0001) and, more specifically, less cardiovascular complications (p = 0.0007).  
Success rate  
Overall success rate in Italy (Table S4, Supplementary material) was 76.4%, with higher 
freedom from AF in the paroxysmal forms of the arrhythmia (80.0% vs. 70.6% and 66.7% 
for persistent and long-standing persistent AF, respectively). These results, as well as time 
to first recurrence are consistent with those obtained in the other enrolling countries (Table 
4 and Figure 2). The impact of catheter ablation on symptoms severity is also reported in 
Figure 3a and Table S5 (Supplementary material).  
Drugs assumption data is reported in Figure S1 (Supplementary material), at 
admission, discharge, before 12-months visit, and after 1-year follow-up. The major 
changes in drug treatment before and after the catheter ablation regard anticoagulant 
therapy, antiplatelet agents, antiarrhythmic and rate control drugs. The use of amiodarone 
(24% and 12% at baseline and 1-year follow-up, respectively), dronedarone (2% and < 1% 
at baseline and 1-year follow-up, respectively), flecainide (28% and 18% at baseline and 
1-year follow-up, respectively) and digoxin (3% and < 1% at baseline and 1-year follow-
up, respectively) was progressively reduced following AF ablation. At discharge more 
patients were administered VKA and LMWH compared to admission (76% vs. 60% for 
VKA and 37% vs. 23% for LMWH), however in a large portion of patients the treatment 




LMWH, respectively). The reduction in use of anticoagulation therapy was equally 
distributed in patients with different CHA2DS2-VASc scores and was maintained during 
follow-up before and after 12-months visit (Figure 3b).  
Discussion 
Several clinical studies have thoroughly assessed AF management, laying the basis for the 
current guidelines and recommendations [11].  Nevertheless, a "real life" registry, focusing 
on a general, unselected population, holds the potential to describe tendencies among 
categories/groups or even Countries that have not emerged yet. The utility of a National 
survey stems from the fact that many recent studies may not be representative of the 
national territory, as they focus on a singular ablation technique or on patients with a 
certain geographical origin, implying differences in environmental risk factors, genetic 
predisposition and comorbidities[13–16]. Moreover, data derived from clinical studies 
may relate to adoption of specific strategies in AF management and/or indication to 
catheter ablation. In fact, National surveys, focusing on AF epidemiology as the FAI [3] 
are available, whereas similar data on AF ablation are poor. 
Moreover, analysis of data from all participating countries allows regional comparisons, 
providing useful insights to national and supranational health organizations to trace 
politics in order to improve treatments and obtain equal health standards.  
In this prospective the main finding of the present analysis is that Tthe vast majority of AF 
ablations follow 2010 ESC guidelines recommendations, and, despite the data on success 
may be influenced by the lack of a standardized electrographic follow-up, as clearly stated 




in Italy are adequate and consistent with those reported in the other participating countries 
and in previously published RCTs [17,18]. However this outcome is obtained exposing 
patients to a minor rate of adverse events. Speculations on this aspect are difficult, present 
data, in any case, confirm a previous Italian registry[19]Lack of uniformity in data 
collection and under reporting may play a role, at least partially, in the difference detected; 
however specific cardiovascular complications (Table 3), attention towards which is the 
greatest during, at least, hospitalization, are statistically lower suggesting that an effective 
difference might exists. One of the reasons underlying this discrepancy may, indeed, be a 
more extensive use of image integration in Italy 
Of note, the increased use of adjunctive ablation is not accompanied with an improved 
outcome; this could suggest that PVI is sufficient to achieve the desired clinical benefit. 
However, this finding can be driven by the fact that most of the enrolled patients had 
paroxysmal AF; from a single case perspective adjunctive ablation may still be useful in 
selected patients with persistent AF or history of atypical atrial flutter. 
 
Interesting data emerge on oral anticoagulants prescription. More than 50% of the 
patients with a CHA2DS2-VASc score of 0 are prescribed anticoagulants before AF 
ablation and, despite a reduction, 35.2% still assume them after the procedure. On the 
other hand, among patients with a CHA2DS2-VASc score >= 2, 17.6% were not on 
anticoagulation before the procedure. This percentage further increased at 12-month visit, 
most probably due to sinus rhythm recording, despite no clear evidences about the safety 




assumed by more than 10% of patients, and, despite a temporary reduction at discharge 
after the procedure, this percentage is confirmed during follow-up, suggesting that 
education programs aimed at improving Physicians' adherence to guidelines 
recommendations should be encouraged and pursued. 
Concerning procedural characteristics, it must be taken into account that due to the 
recent years technology improvement, actual data may slightly differ from the hereby 
reported. As an example, cryoballoon ablation likely increased [22] after publication of the 
FIRE and ICE trial[23]. Given this, the minor use of cryoablation (usually performed 
under radiological guidance), along with a more diffused imagei integration in Italy, 
probably explain the shorter fluoroscopy time compared to the other countries.  Counter 
intuitively, absorbed radiation dose per square centimeter of body surface area is greater in 
Italy. Caution should be exercised when interpreting these data: firstly there may have 
been no uniformity among centers in the collection of data; secondly this difference could 
stem from the more extensive use of rotational angiography, greater recourse to adjunctive 
ablation, more frequent cavotricuspid isthmus ablation, or poor implementation of new 
generation x ray machines and under utilization of techniques to optimize radiation 
use[24]. In any case, real-world data on this subject are fundamental: ionizing radiation 
represents an important caveat and needs to be considered for both patients and medical 
staff’s safety. Monitoring of the implementation of near-to-zero x ray ablation approaches 




Finally, it must be taken into account during the decision path towards referral for AF 
catheter ablation that the adverse event rate at 1 year is not marginal, being in Italy, albeit 
roughly half than in other Countries, 7.3%.  
 
Limitations 
This study presents some limitations. First the design of the study, limited to 1-year 
follow-up. The analysis was conducted on aggregated data, not enabling considerations on 
subgroups characteristics and, for example, to define whether a more extensive ablation 
could be useful in selected patients. Since the survey included 318 patients, statistical 
under powering may be taken into account; in particular the discrepancy concerning 
complication rates may arise from the fact that generally very rare adverse events might 
not have been, by chance, observed in Italian centers. Finally, due to the rapid advances in 
the field, data may not be representative of the current situation. 
 
Conclusion 
We have reported the ESC-EHRA AF long-term registry findings on AF catheter ablation 
in Italy. Overall success rate in Italy is consistent with that achieved in other participating 
countries, whereas 1-year complications rate is significantly lower. Finally, in Italy, 
despite lower procedure and fluoroscopy times, patients undergoing AF ablation are 
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312 patients with ablation performed
1 patients with ablation partially done
251 patients at 12-month follow-up
Fig. 1 - Patient Flow for ITALY
318 patients included
5 patient without ablation 
(1%)
0 death during the in-
hospital phase
313 patients at discharge





Figure 2: Kaplan-Meier curves for time to first arrhythmia recurrence in Italy versus the 








Figure 5:Kaplan–Meier curves for time to first recurrence in ITALY versus rest of
countries.
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Figure 3: EHRA score for symptoms at inclusion and 1-year follow-up (a) and use of 
































Table 1: Baseline clinical characteristics: Italy vs. other participating countries 
 
 
 Total ITALY Other countries P value 
Age (years)     
   N 3592 313 3279  
   Median (IQR) 59.0 [52.0 - 65.0] 60.0 [54.0 - 66.0] 59.0 [52.0 - 65.0] 0.0510* 
Females (%) 1146/3593 (31.9%) 74/313 (23.6%) 1072/3280 (32.7%) 0.0010** 
Caucasian (%) 3111/3429 (90.7%) 308/313 (98.4%) 2803/3116 (90.0%) <0.0001** 
Body Mass Index >30 kg/m² (%) 1047/3333 (31.4%) 42/268 (15.7%) 1005/3065 (32.8%) <0.0001** 
Cardiovascular risk factors (%)     
   Diabetes mellitus 347/3583 (9.7%) 31/313 (9.9%) 316/3270 (9.7%) 0.8907** 
   Hypertension 1954/3579 (54.6%) 190/311 (61.1%) 1764/3268 (54.0%) 0.0160** 
   Former smokers (>1 year) 653/3432 (19.0%) 40/297 (13.5%) 613/3135 (19.6%) 0.0107** 
   Hypercholesterolemia 1159/3517 (33.0%) 100/308 (32.5%) 1059/3209 (33.0%) 0.8491** 
Ischaemic thromboembolic events 
(%) 
230/3576 (6.4%) 20/313 (6.4%) 210/3263 (6.4%) 0.9747** 
Implanted devices     
   PM 116/3590 (3.2%) 4/313 (1.3%) 112/3277 (3.4%) 0.0408** 
   ICD 27/3588 (0.8%) 3/313 (1.0%) 24/3275 (0.7%) 0.5073*** 
   CRT-P 5/3588 (0.1%) 0 5/3275 (0.2%) NA 




 Total ITALY Other countries P value 
CHA2DS2-VASc     
   0 805/3476 (23.2%) 68/295 (23.1%) 737/3181 (23.2%) 0.5552* 
   1 1038/3476 (29.9%) 94/295 (31.9%) 944/3181 (29.7%) 
   2 810/3476 (23.3%) 66/295 (22.4%) 744/3181 (23.4%) 
   3 525/3476 (15.1%) 48/295 (16.3%) 477/3181 (15.0%) 
   4 197/3476 (5.7%) 13/295 (4.4%) 184/3181 (5.8%) 
   5 70/3476 (2.0%) 5/295 (1.7%) 65/3181 (2.0%) 
   6 24/3476 (0.7%) 0 24/3181 (0.8%) 
   7 7/3476 (0.2%) 1/295 (0.3%) 6/3181 (0.2%) 
HAS-BLED     
   0 2063/3357 (61.5%) 186/284 (65.5%) 1877/3073 (61.1%) 0.1201* 
   1 1009/3357 (30.1%) 79/284 (27.8%) 930/3073 (30.3%) 
   2 241/3357 (7.2%) 16/284 (5.6%) 225/3073 (7.3%) 
   3 39/3357 (1.2%) 2/284 (0.7%) 37/3073 (1.2%) 
   4 5/3357 (0.1%) 1/284 (0.4%) 4/3073 (0.1%) 
   <3 3313/3357 (98.7%) 281/284 (98.9%) 3032/3073 (98.7%) 1.0000*** 
   >=3 44/3357 (1.3%) 3/284 (1.1%) 41/3073 (1.3%) 
Number of AFib episodes in the last 
month 
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   N 1978 189 1789  
   Median (IQR) 3.0 [1.0 - 7.0] 2.0 [1.0 - 4.0] 3.0 [1.0 - 8.0] <0.0001* 
AFib Underlying disorder (%)     
   Lone atrial fibrillation 1165/3593 (32.4%) 97/313 (31.0%) 1068/3280 (32.6%) 0.5706** 
   Hypertension without known 
hypertensive cardiomyopathy 
1336/3579 (37.3%) 49/311 (15.8%) 1287/3268 (39.4%) <0.0001** 
   Hypertensive cardiomyopathy 623/2423 (25.7%) 143/216 (66.2%) 480/2207 (21.7%) <0.0001** 
   Coronary artery disease 449/2380 (18.9%) 25/211 (11.8%) 424/2169 (19.5%) 0.0063** 
   Dilated cardiomyopathy 74/2426 (3.1%) 7/215 (3.3%) 67/2211 (3.0%) 0.8544** 
   Hypertrophic cardiomyopathy 55/2426 (2.3%) 5/215 (2.3%) 50/2211 (2.3%) 0.8134*** 
   Chronic Heart Failure 537/2418 (22.2%) 19/214 (8.9%) 518/2204 (23.5%) <0.0001** 
   Other cardiac disease 158/2415 (6.5%) 9/215 (4.2%) 149/2200 (6.8%) 0.1432** 
   Hyperthyroidism 84/3519 (2.4%) 11/313 (3.5%) 73/3206 (2.3%) 0.1710** 
AFib Precipating factors (%)     
   Physical exercice 389/3502 (11.1%) 7/313 (2.2%) 382/3189 (12.0%) <0.0001** 
   Alcohol abuse 146/3481 (4.2%) 1/313 (0.3%) 145/3168 (4.6%) 0.0003** 
   Heart failure 180/3559 (5.1%) 0 180/3246 (5.5%) NA 
   Thyreotoxicosis 57/3555 (1.6%) 4/313 (1.3%) 53/3242 (1.6%) 0.6312** 
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   Surgical intervention 39/3560 (1.1%) 4/313 (1.3%) 35/3247 (1.1%) 0.7728*** 
   Pulmonary infection 25/3561 (0.7%) 2/313 (0.6%) 23/3248 (0.7%) 1.0000*** 
   Acute pericarditis 3/3564 (0.1%) 0 3/3251 (0.1%) NA 
   Postprandial 158/3489 (4.5%) 10/313 (3.2%) 148/3176 (4.7%) 0.2343** 
Prior history of atrial flutter (%) 840/3461 (24.3%) 87/309 (28.2%) 753/3152 (23.9%) 0.0951** 
   Cavotricuspid-dependent flutter 
(%) 
565/667 (84.7%) 61/77 (79.2%) 504/590 (85.4%) 0.1549** 
EHRA score for symptoms (%)     
   1 107/3589 (3.0%) 24/312 (7.7%) 83/3277 (2.5%) <0.0001* 
   2 1941/3589 (54.1%) 240/312 (76.9%) 1701/3277 (51.9%) 
   3 1391/3589 (38.8%) 43/312 (13.8%) 1348/3277 (41.1%) 
   4 150/3589 (4.2%) 5/312 (1.6%) 145/3277 (4.4%) 
Associated symptoms (EHRA score 
>1) 
3482/3589 (97.0%) 288/312 (92.3%) 3194/3277 (97.5%) <0.0001** 
   Palpitations 2966/3482 (85.2%) 253/288 (87.8%) 2713/3194 (84.9%) 0.1836** 
   Fatigue 1725/3482 (49.5%) 106/288 (36.8%) 1619/3194 (50.7%) <0.0001** 
   Dyspnoea 1424/3482 (40.9%) 93/288 (32.3%) 1331/3194 (41.7%) 0.0019** 
   Weakness 1415/3482 (40.6%) 43/288 (14.9%) 1372/3194 (43.0%) <0.0001** 
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   Chest pain 560/3482 (16.1%) 11/288 (3.8%) 549/3194 (17.2%) <0.0001** 
   Syncope 143/3482 (4.1%) 13/288 (4.5%) 130/3194 (4.1%) 0.7163** 
Prior cardioversions (%) 2292/3457 (66.3%) 223/308 (72.4%) 2069/3149 (65.7%) 0.0176** 
   Electrical 1476/3512 (42.0%) 154/308 (50.0%) 1322/3204 (41.3%) 0.0030** 
   Pharmacological 1365/3400 (40.1%) 131/306 (42.8%) 1234/3094 (39.9%) 0.3191** 
Previous antiarrhythmic drug trial 
(%) 
3202/3558 (90.0%) 291/311 (93.6%) 2911/3247 (89.7%) 0.0279** 
   Flecainide 1084/3178 (34.1%) 169/290 (58.3%) 915/2888 (31.7%) <0.0001** 
   Propafenone 1120/3179 (35.2%) 82/288 (28.5%) 1038/2891 (35.9%) 0.0118** 
   Amiodarone 1686/3184 (53.0%) 131/289 (45.3%) 1555/2895 (53.7%) 0.0065** 
   Sotalol 923/3176 (29.1%) 62/288 (21.5%) 861/2888 (29.8%) 0.0031** 
   Quinidine 34/3172 (1.1%) 5/288 (1.7%) 29/2884 (1.0%) 0.2294*** 
   Dronedarone 256/3173 (8.1%) 10/288 (3.5%) 246/2885 (8.5%) 0.0027** 
   Disopyramide 28/3172 (0.9%) 6/288 (2.1%) 22/2884 (0.8%) 0.0362*** 
   Other 343/3172 (10.8%) 16/288 (5.6%) 327/2884 (11.3%) 0.0026** 
Number of previous drug trials     
   N 3202 291 2911  
   Median (IQR) 1.0 [1.0 - 2.0] 1.0 [1.0 - 2.0] 1.0 [1.0 - 2.0] 0.5426* 
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   Symptoms 3272/3593 (91.1%) 275/313 (87.9%) 2997/3280 (91.4%) 0.0374** 
   Quality of life 2377/3593 (66.2%) 175/313 (55.9%) 2202/3280 (67.1%) <0.0001** 
   Desire for drug-free lifestyle 1068/3593 (29.7%) 77/313 (24.6%) 991/3280 (30.2%) 0.0379** 
   Desire for sinus rhythm 1280/3593 (35.6%) 130/313 (41.5%) 1150/3280 (35.1%) 0.0223** 
Indications according to the 
recommendations of the 2010 ESC 
AFib guidelines 
    
   Paroxysmal AF previously failed 
antiarrhythmic medication (Class 
IIa) 
2146/3593 (59.7%) 170/313 (54.3%) 1976/3280 (60.2%) 0.0409** 
   Persistent symptomatic AF 
refractory to antiarrhythmic 
therapy (Class IIa) 
925/3593 (25.7%) 93/313 (29.7%) 832/3280 (25.4%) 0.0929** 
   Heart failure with antiarrhythmic 
medication, including amiodarone, 
fails to control symptoms (Class IIb) 
53/3593 (1.5%) 13/313 (4.2%) 40/3280 (1.2%) 0.0004*** 
   Prior to antiarrhythmic drug 
therapy in symptomatic patients 
despite adequate rate control with 
paroxysmal AF and no significant 
underlying heart disease (Class IIb) 
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   Symptomatic long-standing 
persistent AF refractory to 
antiarrhythmic drugs (Class IIb) 
147/3593 (4.1%) 5/313 (1.6%) 142/3280 (4.3%) 0.0197** 
   Other 165/3593 (4.6%) 26/313 (8.3%) 139/3280 (4.2%) 0.0010** 
 
 
IQR, interquartile range; SBP, Systolic Blood Pressure; PM, pacemaker; ICD, implantable 
cardioverter defibrillator. CRT, cardiac resynchronization therapy. Unknown or missing values 
are not taken into account. 
*P-values for among-group comparisons are from Kruskal-Wallis test.  
**P-values for among-group comparisons are from Pearson's test.  










Table 2: Technical characteristics of the procedure and ablation strategy by type of atrial 
fibrillation: Italy vs other participating countries 
 
 Total ITALY Other countries P value 
Type of procedure (%)     
   First procedure 2815/3592 (78.4%) 245/313 (78.3%) 2570/3279 (78.4%) 0.9663** 
   Redo due to Atrial Fibrillation 685/3592 (19.1%) 57/313 (18.2%) 628/3279 (19.2%) 0.6855** 
   Redo due to Left Atrial Flutter/Left 
Atrial Tachycardia 
92/3592 (2.6%) 11/313 (3.5%) 81/3279 (2.5%) 0.2639** 
Hybrid AF ablation (%) 11/3592 (0.3%) 0 11/3279 (0.3%) NA 
Use of 3D mapping system (%) 2864/3592 (79.7%) 242/313 (77.3%) 2622/3279 (80.0%) 0.2657** 
Use of remote navigation and 
ablation system (%) 
190/3592 (5.3%) 10/313 (3.2%) 180/3279 (5.5%) 0.0831** 
Use of rotational angiography for 
3D reconstruction (%) 
142/3592 (4.0%) 43/313 (13.7%) 99/3279 (3.0%) <0.0001** 
Use of circular mapping catheter 
(%) 
2937/3592 (81.8%) 224/313 (71.6%) 2713/3279 (82.7%) <0.0001** 
Use of image fusion (%) 1272/3591 (35.4%) 160/313 (51.1%) 1112/3278 (33.9%) <0.0001** 
   CT 986/1272 (77.5%) 64/160 (40.0%) 922/1112 (82.9%) <0.0001** 
   MRI 180/1272 (14.2%) 54/160 (33.8%) 126/1112 (11.3%) <0.0001** 
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   Other 10/1272 (0.8%) 1/160 (0.6%) 9/1112 (0.8%) 1.0000*** 
General anaesthesia during 
procedure (%) 
809/3592 (22.5%) 9/313 (2.9%) 800/3279 (24.4%) <0.0001** 
Energy source (%)     
   Non-irrigated radiofrequency 51/3591 (1.4%) 0 51/3278 (1.6%) NA 
   Radiofrequency with closed 
irrigation 
126/3591 (3.5%) 6/313 (1.9%) 120/3278 (3.7%) 0.1092** 
   Radiofrequency with open 
irrigation 
2751/3591 (76.6%) 290/313 (92.7%) 2461/3278 (75.1%) <0.0001** 
   Cryo 571/3591 (15.9%) 13/313 (4.2%) 558/3278 (17.0%) <0.0001** 
   Duty-cycled radiofrequency 
energy 
61/3591 (1.7%) 5/313 (1.6%) 56/3278 (1.7%) 0.8846** 
   Laser balloon (endoscopic 
ablation system) 
25/3591 (0.7%) 0 25/3278 (0.8%) NA 
   High intensity focused ultrasound 8/3591 (0.2%) 0 8/3278 (0.2%) NA 
Procedure duration (min)     
   N 3339 289 3050  
   Median (IQR) 160.0 [120.0 - 200.0] 145.0 [110.0 - 180.0] 160.0 [120.0 - 200.0] 0.0005* 
Fluoroscopy total time (min)     
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   Median (IQR) 19.7 [10.7 - 33.1] 16.9 [8.4 - 29.7] 20.0 [11.0 - 33.8] 0.0018* 
Radiation dose (mGy)     
   N 891 53 838  
   Median (IQR) 386.0 [167.0 - 852.0] 477.0 [170.0 - 758.0] 379.0 [167.0 - 889.0] 0.9038* 
Radiation dose (Gy/cm²)     
   N 1872 158 1714  
   Median (IQR) 27.3 [10.0 - 59.5] 37.5 [19.0 - 65.5] 26.0 [9.5 - 59.3] 0.0022* 
Transesophageal echocardiogram 
(%) 
550/2783 (19.8%) 0 550/2542 (21.6%) NA 
Intracardiac echocardiogram (%) 457/3592 (12.7%) 7/313 (2.2%) 450/3279 (13.7%) <0.0001** 
Esophageal monitoring during 
procedure (%) 
319/3592 (8.9%) 34/313 (10.9%) 285/3279 (8.7%) 0.1970** 
   Temperature probe 277/319 (86.8%) 31/34 (91.2%) 246/285 (86.3%) 0.5940*** 
   Electroanatomical mapping 5/319 (1.6%) 3/34 (8.8%) 2/285 (0.7%) 0.0096*** 
   Transeophageal echo 36/319 (11.3%) 0 36/285 (12.6%) NA 
   Other 1/319 (0.3%) 0 1/285 (0.4%) NA 
Attempt of PV isolation (overall) (%) 3509/3548 (98.9%) 306/308 (99.4%) 3203/3240 (98.9%) 0.5758*** 
Achievement of PV entrance block 
(%) 
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   LSPV 3261/3374 (96.7%) 297/301 (98.7%) 2964/3073 (96.5%) 0.0412** 
   LIPV 3193/3293 (97.0%) 288/290 (99.3%) 2905/3003 (96.7%) 0.0147** 
   RSPV 3236/3359 (96.3%) 281/288 (97.6%) 2955/3071 (96.2%) 0.2446** 
   RIPV 3206/3352 (95.6%) 287/291 (98.6%) 2919/3061 (95.4%) 0.0091** 
Atrial linear lesion (overall) (%) 1156/3540 (32.7%) 102/312 (32.7%) 1054/3228 (32.7%) 0.9884** 
Left atrial linear lesion (%) 606/3527 (17.2%) 52/312 (16.7%) 554/3215 (17.2%) 0.8006** 
   Roof line 511/3591 (14.2%) 45/312 (14.4%) 466/3279 (14.2%) 0.9186** 
   Mitral isthmus line 262/3591 (7.3%) 32/312 (10.3%) 230/3279 (7.0%) 0.0354** 
   Posterior line 160/3515 (4.6%) 36/312 (11.5%) 124/3203 (3.9%) <0.0001** 
   Other left atrial linear lesion 122/3591 (3.4%) 14/312 (4.5%) 108/3279 (3.3%) 0.2662** 
Right atrial linear lesion (%) 716/3530 (20.3%) 66/312 (21.2%) 650/3218 (20.2%) 0.6888** 
   Superior vena cava 57/3591 (1.6%) 2/312 (0.6%) 55/3279 (1.7%) 0.2324*** 
   Cavotricuspid  isthmus ablation 660/3591 (18.4%) 55/312 (17.6%) 605/3279 (18.5%) 0.7200** 
   Other right atrial linear lesion 29/3515 (0.8%) 10/312 (3.2%) 19/3203 (0.6%) 0.0001*** 
Ablation at fractionated 
electrogram sites (%) 
349/3590 (9.7%) 63/311 (20.3%) 286/3279 (8.7%) <0.0001** 
Ablation of autonomic ganglionated 
plexi 
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Use of adenosine at end of 
procedure (%) 
367/3591 (10.2%) 37/312 (11.9%) 330/3279 (10.1%) 0.3172** 
 
 
Unknown or missing values are not taken into account. 
*P-values for among-group comparisons are from Kruskal-Wallis test.  
**P-values for among-group comparisons are from Pearson's test.  





Table 3: Adverse events associated with catheter ablation of atrial fibrillation: Italy vs other 
participating countries 
 
 Total ITALY 
Other countries 
(n=3280) P value 
Cardiovascular (%) 176/3592 (4.9%) 3/313 (1.0%) 173/3279 (5.3%) 0.0007** 
   Pericarditis 30/3591 (0.8%) 2/313 (0.6%) 28/3278 (0.9%) 1.0000*** 
   Cardiac perforation 52/3591 (1.4%) 0 52/3278 (1.6%) NA 
   Acute myocardial Infarction 2/3591 (0.1%) 0 2/3278 (0.1%) NA 
   Endocarditis 2/3591 (0.1%) 0 2/3278 (0.1%) NA 
   Atypical atrial flutter (no AFib) 11/3592 (0.3%) 0 11/3279 (0.3%) NA 
   Bradycardia Requiring Pacemaker 10/3591 (0.3%) 1/313 (0.3%) 9/3278 (0.3%) 0.5988*** 
   Cardiac Arrest 3/3591 (0.1%) 0 3/3278 (0.1%) NA 
   Air embolism 9/3591 (0.3%) 0 9/3278 (0.3%) NA 
   Cardiac thromboembolic event 2/3591 (0.1%) 0 2/3278 (0.1%) NA 
   Heart valve damage 3/3591 (0.1%) 0 3/3278 (0.1%) NA 
   Other 69/3591 (1.9%) 0 69/3278 (2.1%) NA 
Peripheral/Vascular (%) 64/3592 (1.8%) 3/313 (1.0%) 61/3279 (1.9%) 0.2492** 
   AV fistula 22/3592 (0.6%) 1/313 (0.3%) 21/3279 (0.6%) 0.7159*** 
   Pseudoaneurysm 24/3592 (0.7%) 1/313 (0.3%) 23/3279 (0.7%) 0.7171*** 
   Hematoma or bleeding requiring 
evacuation or transfusion 
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   Peripheral thromboembolic event 1/3592 (0.0%) 0 1/3279 (0.0%) NA 
   Deep vein thrombosis 2/3592 (0.1%) 0 2/3279 (0.1%) NA 
Neurological (%) 35/3592 (1.0%) 0 35/3279 (1.1%) NA 
   Stroke 5/3592 (0.1%) 0 5/3279 (0.2%) NA 
   TIA 14/3592 (0.4%) 0 14/3279 (0.4%) NA 
   Phrenic Nerve Damage 16/3592 (0.4%) 0 16/3279 (0.5%) NA 
Pulmonary (%) 21/3592 (0.6%) 4/313 (1.3%) 17/3279 (0.5%) 0.1040*** 
   Hemothorax 1/3592 (0.0%) 0 1/3279 (0.0%) NA 
   Pleural Effusion 5/3592 (0.1%) 0 5/3279 (0.2%) NA 
   Pneumothorax 5/3592 (0.1%) 1/313 (0.3%) 4/3279 (0.1%) 0.3663*** 
   Pulmonary vein stenosis 7/3592 (0.2%) 3/313 (1.0%) 4/3279 (0.1%) 0.0176 *** 
   Pneumonia 3/3592 (0.1%) 0 3/3279 (0.1%) NA 
Gastrointestinal (%) 7/3592 (0.2%) 0 7/3279 (0.2%) NA 
   Oesophageal ulceration 3/3592 (0.1%) 0 3/3279 (0.1%) NA 
   Esophageal fistula or perforation 1/3592 (0.0%) 0 1/3279 (0.0%) NA 
   Gastric motility/pyloric spam 
disorders 
3/3592 (0.1%) 0 3/3279 (0.1%) NA 
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   Allergic Reaction 11/3592 (0.3%) 2/313 (0.6%) 9/3279 (0.3%) 0.2479*** 
   Sepsis 1/3592 (0.0%) 0 1/3279 (0.0%) NA 
Other (%) 108/3591 (3.0%) 2/313 (0.6%) 106/3278 (3.2%) 0.0102** 
Death (%) 15/3593 (0.4%) 1/313 (0.3%) 14/3280 (0.4%) 1.0000*** 
   Cardiac 4/15 (26.7%) 0 4/14 (28.6%) NA 
   Vascular 4/15 (26.7%) 1/1 (100%) 3/14 (21.4%) NA 
   Non Cardiovascular 7/15 (46.7%) 0 7/14 (50.0%) NA 
Overall (%) 568/3593 (15.8%) 23/313 (7.3%) 545/3280 (16.6%) <0.0001** 
 
 
AV, atrioventricular; TIA, Transient Ischemic Attack. 
*P-values for among-group comparisons are from Kruskal-Wallis test.  
**P-values for among-group comparisons are from Pearson's test. 





Table 4: Overall success rates in relationship with the type of atrial fibrillation: Italy vs other 
participating countries 
 
 Total ITALY Other countries P value 
Paroxysmal AF 1566/2085 (75.1%) 124/155 (80.0%) 1442/1930 (74.7%) 0.1432** 
Persistent AF 587/828 (70.9%) 60/85 (70.6%) 527/743 (70.9%) 0.9478** 
Long Standing Persistent AF 99/146 (67.8%) 4/6 (66.7%) 95/140 (67.9%) 1.0000*** 
Overall 2252/3059 (73.6%) 188/246 (76.4%) 2064/2813 (73.4%) 0.2980** 
 
 
No discontinuation of antiarrhythmic drugs was required by the protocol. 
**P-values for among-group comparisons are from Pearson's test.  
***P-values for among-group comparisons are from Fisher’s exact test. 
 
 
 
